New Developments in Pharmacological Obesity Treatments

The NHS is introducing the weight-loss injection Mounjaro (tirzepatide), which has delivered more than a 20% reduction in body weight during clinical trials—outperforming existing treatments. While its use is currently restricted to individuals with severe obesity (BMI ≥35 with related health issues), its wider availability raises ongoing concerns regarding access and fairness.

Exploring Mounjaro as a Weight Loss Aid in the UK

As interest grows in Mounjaro for managing weight, it's vital for UK residents to understand where and how this medication can be accessed.

1. UK Licensing Status

Tirzepatide, sold as Mounjaro, has received UK authorisation for managing type 2 diabetes. Its use for obesity, however, is considered off-label. This implies that though not formally approved for weight loss, clinicians may prescribe it based on their discretion and a patient’s specific condition.

2. Getting a Prescription

Mounjaro requires a prescription from a licensed healthcare provider. While NHS prescriptions focus on blood sugar management in diabetics, some private medical centres offer off-label prescriptions for weight reduction, subject to strict medical oversight.

3. NHS Access Limitations

Within the NHS, Mounjaro is currently prescribed for type 2 diabetes under strict criteria. Wider use for treating obesity is under consideration and will depend on future approvals from regulatory organisations like NICE.

4. Private Sector Pathways

Private clinics can offer Mounjaro to patients for weight management purposes. These providers typically perform a full medical assessment beforehand. Since pricing varies, prospective users should compare providers and consult qualified clinicians.

5. Clinical Trials in Progress

Clinical research is actively investigating tirzepatide’s weight loss potential. The results from ongoing trials could influence future regulatory decisions and possibly lead to extended approvals in the UK. Staying updated is recommended for interested patients.

Condition	UK Status (2024)
Type 2 Diabetes	Approved with prescription
Weight Loss	Off-label, limited to private providers

Source: UK Medicines and Healthcare products Regulatory Agency (MHRA), 2024.

NHS Prescription Criteria for Tirzepatide (Mounjaro)

Within the NHS, Mounjaro is prescribed following detailed criteria to ensure its effectiveness and cost-efficiency in managing type 2 diabetes.

1. Confirmed Diagnosis of Type 2 Diabetes

To be eligible, patients must have a medically verified diagnosis of type 2 diabetes, typically supported by HbA1c or other blood test results.

2. Inadequate Control with Other Treatments

Mounjaro is generally used after conventional interventions such as metformin or lifestyle changes have failed to manage blood sugar to target levels.

3. Obesity Consideration

Due to the strong connection between obesity and diabetes, NHS recommendations may favour patients with a BMI of 30 kg/m² or above when prescribing Mounjaro.

4. No Disqualifying Health Conditions

Patients must not have certain medical risks, including past cases of thyroid cancer or pancreatitis, which are contraindications. A full health check is essential.

5. Specialist-Managed Care

Endocrinologists or other specialists typically oversee the prescription and monitoring of Mounjaro due to the complexity of its use and potential risks.

Eligibility Criteria	Description
Diagnosed Type 2 Diabetes	Verified via blood glucose/HbA1c testing
Inadequate Glycaemic Control	When standard therapies prove insufficient
High BMI	Focus on patients with BMI ≥30 kg/m²
Absence of Contraindicating Factors	Excludes those with relevant medical conditions
Specialist Involvement	Usually prescribed and monitored by an endocrinologist

Source: National Institute for Health and Care Excellence (NICE), 2024.

Comparing Mounjaro and Wegovy in Weight Reduction

Both Mounjaro and Wegovy are used to support weight loss, but their mechanisms and results differ. Here’s how they compare:

1. Mechanism of Action

Mounjaro is a dual-action medication that targets both GIP and GLP-1 receptors. This dual activity enhances insulin production, suppresses glucagon, and slows digestion. Wegovy only acts on GLP-1 receptors, regulating appetite and food intake.

2. Effectiveness in Clinical Use

Research shows Mounjaro may result in greater weight loss compared to Wegovy. In clinical trials, Mounjaro users lost up to 22.5% of body weight, while Wegovy users saw an average of 15% loss. However, outcomes vary based on lifestyle and compliance.

3. Side Effects

Nausea and vomiting are common side effects for both medications. Reports suggest that Mounjaro may induce nausea more frequently, though individual tolerance plays a role.

4. Usage and Dosage

Each is delivered as a weekly subcutaneous injection. Though both follow titration schedules, the protocols and devices may differ between products.

5. Price and Accessibility

Cost remains a hurdle for many patients. Accessibility and affordability vary by location, healthcare provider, and insurance coverage.

Medication	Average Weight Loss (%)	Mechanism
Mounjaro	Up to 22.5%	Dual GIP & GLP-1 receptor agonist
Wegovy	Around 15%	GLP-1 receptor agonist

Data Source: 2024 Clinical Trials.

Mechanisms Behind Weight Loss Injections

Weight management injections assist in reducing body weight through several physiological actions:

1. Appetite Regulation

GLP-1 receptor agonists simulate hormones that enhance satiety, causing reduced appetite and fewer calories consumed.

2. Metabolic Effects

Some agents aim to elevate metabolic rates, increasing calorie burning. The level of effectiveness varies across individuals.

3. Fat Absorption Inhibition

Certain medications work within the digestive system to limit the absorption of fat, leading to its excretion instead of being stored.

Injection Type	Primary Mechanism
GLP-1 Receptor Agonists	Appetite regulation
Lipase Inhibitors	Fat absorption prevention

Source: UK National Health Service, 2024

Online Access to Weight Loss Treatments

The process of obtaining weight loss medications through online platforms has grown in popularity due to its convenience. Here's how it typically works:

1. Digital Health Evaluation

Patients complete an online health form outlining their medical history, medications, and weight goals. Some services also conduct a live consultation for better safety.

2. Medication Dispatch

Once a clinician reviews and approves the case, the prescription is fulfilled and sent directly to the patient’s address in discreet packaging.

3. Continued Guidance

Most credible providers offer ongoing support—ranging from dietary advice to medical monitoring—to ensure optimal outcomes and safety.

Frequently Asked Questions

Q1: Is Mounjaro approved for treating obesity in the UK?
A: No, it is currently approved for type 2 diabetes. Use for weight loss remains off-label and under review for broader approval.

Q2: Who qualifies for Mounjaro via the NHS?
A: Patients must have diagnosed type 2 diabetes, have failed other therapies, meet BMI criteria, and be under the care of a specialist without contraindicating health issues.

Q3: What’s the difference between Mounjaro and Wegovy?
A: Mounjaro targets both GIP and GLP-1 receptors, while Wegovy acts only on GLP-1. Mounjaro has shown superior weight loss in trials.

Q4: How do these injections promote weight loss?
A: They work by suppressing appetite, boosting metabolism, or preventing fat absorption—depending on the drug’s formulation.

Q5: Can I get these medications online?
A: Yes, via online services that provide a virtual consultation and ship the medicine directly, often with ongoing medical support.

References:

07/04/2025